Around 1546, Lucas Cranach the Elder painted The Fountain of Youth. On the left, old women arrive on carts, on wheelbarrows and on the backs of attendants. They step into a pool, and on the right they climb out young, are dressed in fresh clothes and go on to a banquet. Nobody in the painting asks what is in the water.

Patients now ask me about the modern version, a vial of exosome treatment. Exosomes are tiny membrane-bound packages that cells release, and products made from them are sold as signals that tell skin to regenerate. The pitch is simple and seductive: a fountain of youth, delivered by needle.

My argument is that exosome treatment has a real but early efficacy signal, and that injecting it into the skin is the part that deserves the most suspicion, because the documented harm sits there and the regulatory status is unsettled. Three papers and one regulatory notice carry the case: a 2026 systematic review and meta-analysis in Aesthetic Surgery Journal, a 2025 case series and a 2024 case report in the Journal of Cosmetic Dermatology, and a 2019 safety notification from the US Food and Drug Administration (FDA). I could read only the abstracts of the three papers, so what follows is limited to what those abstracts report.

Do exosome treatments improve skin? What a 39-study meta-analysis found

Pooled across human studies, exosome-based treatments were associated with average improvements of about 15% to 23% on skin measures, and 20.2% for facial wrinkles (Stack et al., 2026). The authors searched Medline, Embase, Cochrane, the Trip Database and ClinicalTrials.gov on February 2, 2025. They included 39 studies, 26 on skin and 13 on hair, reporting outcomes such as wrinkles, pigmentation, elasticity, texture, erythema and overall appearance (Stack et al., 2026).

The pooled facial wrinkle reduction was 20.2% (95% CI, 15.3% to 25.2%; P < .001), and other skin measures improved by 14.7% to 23.4%. For hair, density rose by 23.6% (95% CI, 18.1% to 29.0%) and thickness by 18.0% (95% CI, 11.1% to 24.9%) (Stack et al., 2026). The review also identified nine ongoing trials in the United States, Iran and China (Stack et al., 2026).

Read those numbers with the design in mind. The abstract describes pooled percent improvement. It does not say how many of the 39 studies compared exosomes with a placebo or untreated skin, and that distinction matters, because skin often looks better during a study for reasons unrelated to the product. The authors themselves note that heterogeneity and nonstandardized protocols limit how far the results generalize, and they graded the evidence as level 3 (therapeutic), which sits below the levels reserved for well-designed randomized trials (Stack et al., 2026). The abstract also does not report how many of the skin studies used injection and how many used topical application.

What went wrong when exosomes were injected into the skin?

The documented complications after intradermal injection were severe and lasting, but they come from case reports that cannot say how common they are (Park, 2025; Tawanwongsri & Vachiramon, 2024).

In a 2024 case report in the Journal of Cosmetic Dermatology, a middle-aged man received multiple injections of a lyophilized (freeze-dried) exosome product for enlarged facial pores. Pain and dark red bumps appeared soon afterward, and within three days they became painful, non-blanching purplish papules and nodules with tiny crusted erosions at the center. When he later received the leftover product intradermally in the upper arm, similar lesions developed. A skin biopsy showed necrotic keratinocytes, leukocytoclastic vasculitis (inflammation of small blood vessels) and eccrine (sweat gland) necrosis. Seven days of oral prednisolone markedly improved the lesions, though post-inflammatory hyperpigmentation remained (Tawanwongsri & Vachiramon, 2024).

A 2025 case series in the same journal described four adult women who developed persistent redness, nodules, granulomatous inflammation and scarring after intradermal injection of unregulated exosome-based products in a nonclinical setting. Treatment included systemic and intralesional corticosteroids, laser therapy and surgical removal, and all four had incomplete resolution with residual scarring (Park, 2025).

Are injected exosomes approved? What regulators and authors say

The sources describe injected exosome use as unapproved or unregulated, though they word it differently. The FDA's notification of December 6, 2019 states that there are currently no FDA-approved exosome products. It reports multiple serious adverse events in patients in Nebraska who were treated with unapproved products marketed as containing exosomes, and says exosomes used to treat disease in humans are generally regulated as drugs and biological products that require premarket review (FDA, 2019).

The 2025 case series states that intradermal injection of exosome products is off-label and unregulated in many countries, including South Korea (Park, 2025). The 2024 case report says most exosome products are approved only for topical use and that subdermal injection has not been approved (Tawanwongsri & Vachiramon, 2024). The FDA notice is from 2019 and concerns the United States, and I have not checked later statements from other regulators. The differences in wording are themselves a reason to ask for the paperwork.

The strongest objection

Some will say that case reports are anecdotes, and that a meta-analysis of 39 studies should outweigh one man and four women. That is partly true. A case report cannot tell you how often a complication happens, and a pooled analysis is the better guide to average benefit (Stack et al., 2026).

But the two kinds of evidence answer different questions. The meta-analysis tells us what happened on average in studies with nonstandardized protocols, graded at level 3 (Stack et al., 2026). The case reports tell us how bad the outcome can be when something goes wrong: necrosis, granulomatous inflammation and scarring that did not fully resolve (Park, 2025; Tawanwongsri & Vachiramon, 2024). An average gain of about 20% on a wrinkle measure is hard to weigh against a scar that stays.

There is a fair caveat on the other side. In the case series the products were unregulated and the setting was nonclinical, so the problem may lie as much with who made and injected the product as with exosomes as a class (Park, 2025). That is a reason to ask about the product and the setting, not a reason to relax.

What should you ask before an exosome treatment?

Start with the product. Ask what is in the vial, who makes it, and what use and route it is approved or registered for in the country where you are being treated. The FDA advises asking whether the agency has reviewed the treatment and requesting the investigational new drug (IND) number (FDA, 2019).

Ask about the route. Topical use is described as approved in some sources, and injection is described as unapproved or unregulated (Park, 2025; Tawanwongsri & Vachiramon, 2024). Ask what the treatment is meant to change and how that will be measured, since the pooled studies measured different things in different ways (Stack et al., 2026). And ask who will manage a complication, because in the reports that meant corticosteroids and, in some cases, laser or surgical removal (Park, 2025; Tawanwongsri & Vachiramon, 2024).

The Clinical Bottom Line

Exosome-based treatment has an early efficacy signal. A 2026 meta-analysis of 39 human studies reported average improvements of about 15% to 23% on skin measures (Stack et al., 2026). The caution is about the route and the label. Injection into the skin is where the severe complications were documented, in case reports, and where the sources describe the regulatory status as unapproved or unregulated (FDA, 2019; Park, 2025; Tawanwongsri & Vachiramon, 2024).

What we still lack are randomized trials with a clear comparison group, standardized protocols, long follow-up, and safety data that can give a rate instead of a story. Until then, a patient is entitled to ask for the product name, the approval status and the plan for complications, and a clinic should be glad to answer.

Cranach's women stepped out of the pool younger, and nobody checked the label on the water. Today, someone should.

For clinical assessments and consultation in Seoul: itsdrbock.com

References

Park, K. Y. (2025). Adverse reactions following intradermal injection of exosome-based formulations: A case series. Journal of Cosmetic Dermatology, 24(10), Article e70520. https://doi.org/10.1111/jocd.70520

Stack, E. R., Spongberg, C., Braud, S. C., Stanton, W. N., & Elway, M. (2026). Clinical advances in exosome-based therapies for aesthetic medicine: A systematic review and meta-analysis of human clinical trials. Aesthetic Surgery Journal, 46(Supplement_1), S13–S25. https://doi.org/10.1093/asj/sjaf178

Tawanwongsri, W., & Vachiramon, V. (2024). Skin necrosis after intradermal injection of lyophilized exosome: A case report and a review of the literature. Journal of Cosmetic Dermatology, 23(5), 1597–1603. https://doi.org/10.1111/jocd.16206

U.S. Food and Drug Administration. (2019, December 6). Public safety notification on exosome products. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-products